FDA GRANTS FAST TRACK DESIGNATION TO PLEOPHARMA, INC’s INVESTIGATIONAL NEW DRUG, PP-01, FOR THE MITIGATION OF CANNABIS WITHDRAWAL SYMPTOMS IN PATIENTS WITH CANNABIS USE DISORDER: A POTENTIAL FIRST IN CLASS TREATMENT

Fast Track Designation highlights the potential of PP-01 to address a serious and unmet need for patients with Cannabis Use Disorder Phase 3 Preparations Underway PHOENIXVILLE, Pa., Feb. 13, 2025 /PRNewswire/ — PleoPharma, Inc., a privately held company focused on finding treatments for…